Literature DB >> 28160285

Lessons Learned: Transfer of the High-Definition Circulating Tumor Cell Assay Platform to Development as a Commercialized Clinical Assay Platform.

P Kuhn1, S M Keating2, G T Baxter2, K Thomas2, A Kolatkar1, C C Sigman2.   

Abstract

Planning and transfer of a new technology platform developed in an academic setting to a start-up company for medical diagnostic product development may appear daunting and costly in terms of complexity, time, and resources. In this review we outline the key steps taken and lessons learned when a technology platform developed in an academic setting was transferred to a start-up company for medical diagnostic product development in the interest of elucidating development toolkits for academic groups and small start-up companies starting on the path to commercialization and regulatory approval.
© 2017, The American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2017        PMID: 28160285      PMCID: PMC5653379          DOI: 10.1002/cpt.645

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

1.  Small business development for molecular diagnostics.

Authors:  Anthanasia Anagostou; Lance A Liotta
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Assessing the clinical utility of diagnostics used in drug therapy.

Authors:  J Woodcock
Journal:  Clin Pharmacol Ther       Date:  2010-10-27       Impact factor: 6.875

3.  Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.

Authors:  Dena Marrinucci; Kelly Bethel; Anand Kolatkar; Madelyn S Luttgen; Michael Malchiodi; Franziska Baehring; Katharina Voigt; Daniel Lazar; Jorge Nieva; Lyudmila Bazhenova; Andrew H Ko; W Michael Korn; Ethan Schram; Michael Coward; Xing Yang; Thomas Metzner; Rachelle Lamy; Meghana Honnatti; Craig Yoshioka; Joshua Kunken; Yelena Petrova; Devin Sok; David Nelson; Peter Kuhn
Journal:  Phys Biol       Date:  2012-02-03       Impact factor: 2.583

4.  High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis.

Authors:  Jorge Nieva; Marco Wendel; Madelyn S Luttgen; Dena Marrinucci; Lyudmila Bazhenova; Anand Kolatkar; Roger Santala; Brock Whittenberger; James Burke; Melissa Torrey; Kelly Bethel; Peter Kuhn
Journal:  Phys Biol       Date:  2012-02-03       Impact factor: 2.583

5.  Randomized clinical trials with biomarkers: design issues.

Authors:  Boris Freidlin; Lisa M McShane; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2010-01-14       Impact factor: 13.506

6.  Case study of the morphologic variation of circulating tumor cells.

Authors:  Dena Marrinucci; Kelly Bethel; Richard H Bruce; Douglas N Curry; Ben Hsieh; Mark Humphrey; Robert T Krivacic; Joan Kroener; Lindsay Kroener; Andras Ladanyi; Nicole H Lazarus; Jorge Nieva; Peter Kuhn
Journal:  Hum Pathol       Date:  2006-12-22       Impact factor: 3.466

7.  Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.

Authors:  W Jeffrey Allard; Jeri Matera; M Craig Miller; Madeline Repollet; Mark C Connelly; Chandra Rao; Arjan G J Tibbe; Jonathan W Uhr; Leon W M M Terstappen
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

8.  Cytomorphology of circulating colorectal tumor cells:a small case series.

Authors:  Dena Marrinucci; Kelly Bethel; Daniel Lazar; Jennifer Fisher; Edward Huynh; Peter Clark; Richard Bruce; Jorge Nieva; Peter Kuhn
Journal:  J Oncol       Date:  2010-01-06       Impact factor: 4.375

9.  High speed detection of circulating tumor cells.

Authors:  H Ben Hsieh; Dena Marrinucci; Kelly Bethel; Douglas N Curry; Mark Humphrey; Robert T Krivacic; Joan Kroener; Lindsay Kroener; Andras Ladanyi; Nicole Lazarus; Peter Kuhn; Richard H Bruce; Jorge Nieva
Journal:  Biosens Bioelectron       Date:  2006-02-07       Impact factor: 10.618

10.  The new (challenging) role of academia in biomaterial translational research and medical device development.

Authors:  Kyle Kleinbeck; Edward Anderson; Matthew Ogle; Jeanine Burmania; W John Kao
Journal:  Biointerphases       Date:  2012-02-17       Impact factor: 2.456

View more
  4 in total

Review 1.  Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development.

Authors:  Abhijit Pal; Rajiv Shinde; Manuel Selvi Miralles; Paul Workman; Johann de Bono
Journal:  Nat Rev Clin Oncol       Date:  2021-03-24       Impact factor: 66.675

Review 2.  Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?

Authors:  James J Harding; Danny N Khalil; Ghassan K Abou-Alfa
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

3.  Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.

Authors:  François-Clément Bidard; Nicolas Kiavue; Marc Ychou; Luc Cabel; Marc-Henri Stern; Jordan Madic; Adrien Saliou; Aurore Rampanou; Charles Decraene; Olivier Bouché; Michel Rivoire; François Ghiringhelli; Eric Francois; Rosine Guimbaud; Laurent Mineur; Faiza Khemissa-Akouz; Thibault Mazard; Driffa Moussata; Charlotte Proudhon; Jean-Yves Pierga; Trevor Stanbury; Simon Thézenas; Pascale Mariani
Journal:  Cells       Date:  2019-05-28       Impact factor: 6.600

4.  Characterization of Cellular and Acellular Analytes from Pre-Cystectomy Liquid Biopsies in Patients Newly Diagnosed with Primary Bladder Cancer.

Authors:  Stephanie N Shishido; Salmaan Sayeed; George Courcoubetis; Hooman Djaladat; Gus Miranda; Kenneth J Pienta; Jorge Nieva; Donna E Hansel; Mihir Desai; Inderbir S Gill; Peter Kuhn; Jeremy Mason
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.